A new investigation, "A Canadian Initiative: Exploring Adult Pulmonary Hypertension," highlights critical issues such as diagnostic delays and accessibility challenges faced by PH patients. This comprehensive report, developed by RESPIPLUS in collaboration with PHA Canada and other leading organizations, offers valuable insights and recommendations for improving PH care.
top of page
Recent Posts
We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed on Health Canada's website with the mention “Being reviewed und
bottom of page